Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for ANB033 (anti-CD122 antagonist antibody) in Inflammatory disease. The expected timing is based on the latest available company guidance and may change.
8/5/24 Accepts IND,Ph1 initiation in Q4 '24. 11/5/24- Ph1 initiated in October 2024. 8/6/25- Ph1b in celiac disease initiation in Q4 2025. 11/04/25:- Ph1b in celiac initiated; top-line Ph1b data expected Q4 2026; second Ph1b trial planned 2026. 03/03/26:- Ph1b celiac cohorts ongoing; topline Q4 2026. Eosinophilic esophagitis Ph1b initiated Q1 2026; data 2027.
Verification
Confirm timing and program details against the company announcement or filing.